If you follow peptide conversations online, you’ve probably heard of BPC-157, TB-500, and the GH secretagogues.
But there’s a compound that rarely makes the “top 5” lists that might deserve to be at the top: GHK-Cu.
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide — just three amino acids bound to a copper ion.
It’s found in human plasma, saliva, and urine, and here’s the kicker: its concentration in your blood drops by about 60% between age 20 and age 60.
That decline mirrors a lot of things we associate with aging — slower wound healing, thinner skin, increased inflammation, reduced tissue remodeling.
And it might not be a coincidence.
What the research shows:
A genomic study by Loren Pickart and colleagues found that GHK-Cu modulates the expression of over 4,000 human genes — roughly 6% of the entire human genome.
That’s an extraordinary regulatory footprint for a molecule this small. Among the genes affected:
Repair: Upregulation of collagen synthesis and tissue remodeling genes
Inflammation: Suppression of pro-inflammatory cytokines (IL-6, TNF-alpha) and activation of anti-inflammatory pathways
Neuroregeneration: Activation of genes involved in nerve growth and neural repair
Antioxidant defense: Upregulation of DNA repair enzymes and antioxidant genes (superoxide dismutase, glutathione)
Anti-aging: Reset of multiple gene expression patterns toward a younger baseline
How people are using it:
GHK-Cu shows up in two main contexts.
Topically, it’s been used in skincare for years — there’s solid clinical data showing it improves skin elasticity, reduces fine lines, and accelerates wound healing.
Some studies have it outperforming vitamin C and retinoic acid for collagen stimulation.
But the more interesting use case is systemic (subcutaneous injection).
Researchers are exploring it for tissue repair, post-surgical recovery, hair growth, lung tissue remodeling, and even as a general anti-aging intervention based on its broad gene-regulatory effects.
Common research dosing is 1–2mg/day subcutaneously, often run for 4–8 week cycles.
The big picture:
Most peptides target a specific receptor or pathway. GHK-Cu is different — it’s more like a master switch that shifts thousands of genes in a “younger” direction simultaneously.
Whether that translates to meaningful clinical outcomes in humans at research doses is still being studied, but the mechanistic data is hard to ignore.
Tomorrow I’m going to teach you something that’ll save you money and potentially keep you safe: how to actually read a Certificate of Analysis so you know whether what you’re buying is real.